In June 2011 NMT Medical (PINK:NMTI) put its intellectual property up for sale as part of its bankruptcy procedure. The firm sold its portfolio of intellectual property portfolio at auction in an attempt to repay its creditors after declaring bankruptcy. NMT Medical, Inc., a medical technology company, designs, develops, manufactures, and markets implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive catheter-based procedures. Its product line comprises CardioSEAL, a cardiac septal repair implant device used for the repair of structural heart disease and intracardiac shunts that result in abnormal blood flow through the chambers of the heart; STARFlex, which incorporates a self-centering system that allows the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function; and BioSTAR, a bioabsorbable patent foramen ovale implant and biological closure technology. The company also develops BioTREK, a biological closure technology, which incorporates a biosynthetic material that uses the body?s own regenerative capability to restore function naturally. It primarily serves hospitals, clinics, and other healthcare centers. The company markets its products through distributors, as well as directly in North America and internationally.
